<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Kodiak Sciences (KOD) 的最新公告已发布。</p>
<p>2025 年 12 月 16 日，Kodiak Sciences Inc. 与一组主要投资银行签订了承销协议，进行其普通股的公开发行，最初覆盖 6,956,522 股，公众发行价格为每股 23.00 美元，承销商以每股 21.62 美元购买，并持有 30 天的选择权，最多可再购买 1,043,478 股。承销商于 2025 年 12 月 17 日全额行使了该选择权，Kodiak 于 2025 年 12 月 18 日完成了总计 8,000,000 股的发行和销售，产生了约 1.84 亿美元的毛收入，扣除费用和开支，增强了公司的资本状况和财务灵活性，以支持其持续的业务和开发活动。</p>
<p>对 (KOD) 股票的最新分析评级为持有，目标价格为 14.00 美元。要查看 Kodiak Sciences 股票的完整分析预测列表，请参见 KOD 股票预测页面。</p>
<p><strong>Spark 对 KOD 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，KOD 被评为表现不佳。</p>
<p>Kodiak Sciences 面临重大财务挑战，收入为零且亏损严重，处于评分范围的下端。其技术指标显示短期积极动能，但由于超买信号和更广泛的下行压力，需谨慎对待。估值反映了早期生物科技公司典型的高风险、高回报情景。</p>
<p>要查看 Spark 对 KOD 股票的完整报告，请点击这里。</p>
<p><strong>关于 Kodiak Sciences 的更多信息</strong></p>
<p>Kodiak Sciences Inc.是一家生物制药公司，专注于开发治疗方案，特别是在眼科领域，并通过普通股的公开发行进入资本市场，以资助其运营和管道开发。</p>
<p><strong>平均交易量：</strong> 982,776</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 12.8 亿美元</p>
<p>在 TipRanks 的股票分析页面上找到 KOD 股票的详细分析。</p>

<p>Kodiak Sciences Inc. 完成了一次公开股票发行，出售了 800 万股，每股价格为 23 美元，筹集了约 1.84 亿美元。这增强了其用于持续业务和开发活动的资本。分析师对 KOD 股票的评级为持有，目标价为 14 美元，而 TipRanks 的人工智能分析师则因财务挑战和超买信号将其视为表现不佳。Kodiak 专注于眼科治疗，并利用股票发行来资助运营</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>The latest announcement is out from Kodiak Sciences ( (KOD) ).</p>
<div class="lb-trans"><p>Kodiak Sciences (KOD) 的最新公告已发布。</p>
</div><p>On December 16, 2025, Kodiak Sciences Inc. entered into an underwriting agreement with a syndicate of major investment banks for a public offering of its common stock, initially covering 6,956,522 shares at a price to the public of $23.00 per share, with the underwriters purchasing at $21.62 per share and holding a 30-day option for up to an additional 1,043,478 shares. The underwriters exercised this option in full on December 17, 2025, and Kodiak completed the issuance and sale of a total of 8,000,000 shares on December 18, 2025, generating approximately $184 million in gross proceeds before fees and expenses under customary underwriting terms, bolstering the company’s capital position and financial flexibility for its ongoing business and development activities.</p>
<div class="lb-trans"><p>2025 年 12 月 16 日，Kodiak Sciences Inc. 与一组主要投资银行签订了承销协议，进行其普通股的公开发行，最初覆盖 6,956,522 股，公众发行价格为每股 23.00 美元，承销商以每股 21.62 美元购买，并持有 30 天的选择权，最多可再购买 1,043,478 股。承销商于 2025 年 12 月 17 日全额行使了该选择权，Kodiak 于 2025 年 12 月 18 日完成了总计 8,000,000 股的发行和销售，产生了约 1.84 亿美元的毛收入，扣除费用和开支，增强了公司的资本状况和财务灵活性，以支持其持续的业务和开发活动。</p>
</div><p>The most recent analyst rating on (KOD) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Kodiak Sciences stock, see the KOD Stock Forecast page.</p>
<div class="lb-trans"><p>对 (KOD) 股票的最新分析评级为持有，目标价格为 14.00 美元。要查看 Kodiak Sciences 股票的完整分析预测列表，请参见 KOD 股票预测页面。</p>
</div><p><strong>Spark’s Take on KOD Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 KOD 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, KOD is a Underperform.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，KOD 被评为表现不佳。</p>
</div><p>Kodiak Sciences faces significant financial challenges with no revenue and substantial losses, placing it at the lower end of the scoring range. Its technical indicators show short-term positive momentum, but with caution due to overbought signals and broader downtrend pressures. The valuation reflects the typical high-risk, high-reward scenario of early-stage biotech firms.</p>
<div class="lb-trans"><p>Kodiak Sciences 面临重大财务挑战，收入为零且亏损严重，处于评分范围的下端。其技术指标显示短期积极动能，但由于超买信号和更广泛的下行压力，需谨慎对待。估值反映了早期生物科技公司典型的高风险、高回报情景。</p>
</div><p>To see Spark’s full report on KOD stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 KOD 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Kodiak Sciences</strong></p>
<div class="lb-trans"><p><strong>关于 Kodiak Sciences 的更多信息</strong></p>
</div><p>Kodiak Sciences Inc. is a biopharmaceutical company focused on developing therapies, particularly in ophthalmology, and it accesses capital markets through public offerings of its common stock to fund its operations and pipeline development.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc.是一家生物制药公司，专注于开发治疗方案，特别是在眼科领域，并通过普通股的公开发行进入资本市场，以资助其运营和管道开发。</p>
</div><p><strong>Average Trading Volume:</strong> 982,776</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 982,776</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> $1.28B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 12.8 亿美元</p>
</div><p>Find detailed analytics on KOD stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面上找到 KOD 股票的详细分析。</p>
</div>

Kodiak Sciences 通过完成股票发行成功筹集资金